ANTIBODY-MEDIATED REJECTION OF HUMAN ORTHOTOPIC LIVER ALLOGRAFTS - A STUDY OF LIVER-TRANSPLANTATION ACROSS ABO BLOOD-GROUP BARRIERS AMERICAN JOURNAL OF PATHOLOGY Demetris, A. J., Jaffe, R., Tzakis, A., Ramsey, G., Todo, S., Belle, S., Esquivel, C., Shapiro, R., Markus, B., Mroczek, E., VANTHIEL, D. H., Sysyn, G., Gordon, R., Makowka, L., Starzl, T. 1988; 132 (3): 489-502


A clinicopathologic analysis of liver transplantation across major ABO blood group barriers was carried out 1) to determine if antibody-mediated (humoral) rejection was a cause of graft failure and if humoral rejection can be identified, 2) to propose criteria for establishing the diagnosis, and 3) to describe the clinical and pathological features of humoral rejection. A total of 51 (24 primary) ABO-incompatible (ABO-I) liver grafts were transplanted into 49 recipients. There was a 46% graft failure rate during the first 30 days for primary ABO-I grafts compared with an 11% graft failure rate for primary ABO compatible (ABO-C), crossmatch negative, age, sex and priority-matched control patients (P less than 0.02). A similarly high early graft failure rate (60%) was seen for nonprimary ABO-I grafts during the first 30 days. Clinically, the patients experienced a relentless rise in serum transaminases, hepatic failure, and coagulopathy during the first weeks after transplant. Pathologic examination of ABO-I grafts that failed early demonstrated widespread areas of geographic hemorrhagic necrosis with diffuse intraorgan coagulation. Prominent arterial deposition of antibody and complement components was demonstrated by immunoflourescent staining. Elution studies confirmed the presence of tissue-bound, donor-specific isoagglutinins within the grafts. No such deposition was seen in control cases. These studies confirm that antibody mediated rejection of the liver occurs and allows for the development of criteria for establishing the diagnosis.

View details for Web of Science ID A1988Q131200011

View details for PubMedID 3046369

View details for PubMedCentralID PMC1880751